ERBB2 and breast cancer: There are few reports on clinicopathological characteristics; one report compared 30 LFS breast cancers with 79 sporadic cases and showed a significantly higher rate of HER2 positivity in the LFS group (67% vs. 25%, respectively; p<0.001)14).